Bio-rad Laboratories, Inc. · NYSE:BIO

Bio-rad Laboratories — Investor Day (December 2020)

12 slides from Bio-rad Laboratories's investor day presentation, Dec 10, 2020

  1. Slide 1: Outlook: 2021 – 2023

    OUTLOOK: 2021 – 2023 Bio-Rad Laboratories, Inc. December 10, 2020 © 2020 Bio-Rad Laboratories, Inc. All rights reserved.

  2. Slide 2: Forward-Looking Statements & Use of Non-GAAP Reporting

    FORWARD-LOOKING STATEMENTS & USE OF NON-GAAP REPORTING Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals

  3. Slide 3: Progress Since Our Last Investor Day

    PROGRESS SINCE OUR LAST INVESTOR DAY 21.3% $2.45B Performance driven by: Cell biology markets $2.31B 17.5% ddPCR™ products $2.29B 16.2% Biopharma focus 15.2% Clinical diagnostics $2.16B Global ERP implementation Operating discipline 2017 2018 2019 2020* 2017 2018 2019 2020* Reported Sales Adjusted E

  4. Slide 4: Total Shareholder Return

    TOTAL SHAREHOLDER RETURN 250 125% BIO 190 Equity performance, indexed to 100 (Jan 2018 to Dec 2020) 36% S&P 500 130 S&P 500 35% HC 70 Jan 2018 Jun 2018 Nov 2018 Apr 2019 Sep 2019 Feb 2020 Jul 2020 Dec 2020 BIO S&P 500 S&P 500 HC Source: Bloomberg and Yahoo! Finance from Jan 2, 2018 to Dec 9, 2020 ©

  5. Slide 5: Business and Geographic Mix

    BUSINESS AND GEOGRAPHIC MIX* Biopharma APAC 11% Hospital Labs 21% 38% Academic/Govt Americas 23% Diversified Worldwide 44% Customer Presence Base Applied 3% EMEA Reference Labs Transfusion Labs 35% 13% 12% Consumables / Instrument split of ~65% / ~35% *Business and geographic mix is from 2019 © 2020

  6. Slide 6: Broad Portfolio

    BROAD PORTFOLIO Leading technologies Exciting opportunities Gene expression CFX Opus 96 and 384 qPCR Systems, Sequencing sample prep kits Protein quantitation Maintain leadership and launch of COVID-19 related assays Process media, Pre-packed columns containing Process Scale Resins used for Bioprodu

  7. Slide 7: Driving Growth & Margin Expansion

    DRIVING GROWTH & MARGIN EXPANSION 2020* 2023 Drivers ddPCR™, single-cell, clinical diagnostics, Sales $2.45 – $2.46B** $2.75 – $2.85B bioproduction, biopharma focus Gross margin 56.5% – 57.0% 57.0% – 57.5% Footprint optimization and better capacity utilization Adjusted 21.0% – 21.5%*** 23% – 24% SG&

  8. Slide 8: Outlook Assumptions

    OUTLOOK ASSUMPTIONS ü Stable pricing and macro-environment ü Current foreign exchange rates ü Risk-adjusted revenues from high-growth and emerging markets ü Continued market expansion with ddPCR™ and single-cell products ü Adjusted financial results, excluding special items and any M&A © 2020 Bio-Ra

  9. Slide 9: Elevating Our Sustainability Position

    ELEVATING OUR SUSTAINABILTY POSITION Sustainability program objectives: SOCIAL CAPITAL ü Enhance long-term value for all stakeholders involved – employees, customers, suppliers, investors, competitors, and the environment Access & Affordability Product Selling Practices & Quality & Safety Product La

  10. Slide 10: Appendix

    Appendix © 2020 Bio-Rad Laboratories, Inc. All rights reserved.

  11. Slide 11: Reconciliation to Non-GAAP

    RECONCILIATION TO NON-GAAP Year Ended % of Year Ended % of Year Ended % of December 31, reported December 31, reported December 31, reported ($ and numbers in thousands) 2017 sales 2018 sales 2019 sales Reported Sales $ 2,160,153 $ 2,289,415 $ 2,311,659 GAAP income (loss) from operations $ 119,250 5

  12. Slide 12: © 2020 Bio-Rad Laboratories, Inc. All rights reserved.

    © 2020 Bio-Rad Laboratories, Inc. All rights reserved.

Bio-Rad Laboratories — Investor Day (December 2020) on 6ix